With the key concept of selecting, treating and managing patients with mild cognitive impairment to prevent their condition from deteriorating to the stage of more serious dementia, South Korea's Emocog Inc. is moving closer to becoming the first company in the world to get approval for a digital therapeutic addressing early cognitive decline.
“Mild cognitive impairment [MCI] is also a disease. This stage is seen as the most crucial time. It is a...